Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Oguma, T
   Antitumor drugs possessing topoisomerase I inhibition: applicable separation methods
   JOURNAL OF CHROMATOGRAPHY B
   
   T. Oguma, "Antitumor drugs possessing topoisomerase I inhibition: applicable separation methods", J CHROMAT B, 764(1-2), 2001, pp. 49-58
2. Palumbo, M; Sissi, C; Gatto, B; Moro, S; Zagotto, G
   Quantitation of camptothecin and related compounds
   JOURNAL OF CHROMATOGRAPHY B
   
   M. Palumbo et al., "Quantitation of camptothecin and related compounds", J CHROMAT B, 764(1-2), 2001, pp. 121-140
3. Zufia, L; Aldaz, A; Giraldez, J
   Separation methods for camptothecin and related compounds
   JOURNAL OF CHROMATOGRAPHY B
   
   L. Zufia et al., "Separation methods for camptothecin and related compounds", J CHROMAT B, 764(1-2), 2001, pp. 141-159
4. Ong, SYK; Clarke, SJ; Bishop, J; Dodds, HM; Rivory, LP
   Toxicity of irinotecan (CPT-11) and hepato-renal dysfunction
   ANTI-CANCER DRUGS
   
   S.Y.K. Ong et al., "Toxicity of irinotecan (CPT-11) and hepato-renal dysfunction", ANTI-CANC D, 12(7), 2001, pp. 619-625
5. Boyd, G; Smyth, JF; Jodrell, DI; Cummings, J
   High-performance liquid chromatographic technique for the simultaneous determination of lactone and hydroxy acid forms of camptothecin and SN-38 in tissue culture media and cancer cells
   ANALYTICAL BIOCHEMISTRY
   
   G. Boyd et al., "High-performance liquid chromatographic technique for the simultaneous determination of lactone and hydroxy acid forms of camptothecin and SN-38 in tissue culture media and cancer cells", ANALYT BIOC, 297(1), 2001, pp. 15-24
6. Ratain, MJ
   Insights into the pharmacokinetics and pharmacodynamics of irinotecan
   CLINICAL CANCER RESEARCH
   
   M.J. Ratain, "Insights into the pharmacokinetics and pharmacodynamics of irinotecan", CLIN CANC R, 6(9), 2000, pp. 3393-3394
7. Pitot, HC; Goldberg, RM; Reid, JM; Sloan, JA; Skaff, PA; Erlichman, C; Rubin, J; Burch, PA; Adjei, AA; Alberts, SA; Schaaf, LJ; Elfring, G; Miller, LL
   Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride(CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy
   CLINICAL CANCER RESEARCH
   
   H.C. Pitot et al., "Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride(CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy", CLIN CANC R, 6(6), 2000, pp. 2236-2244
8. Loos, WJ; de Bruijn, P; Verweij, J; Sparreboom, A
   Determination of camptothecin analogs in biological matrices by high-performance liquid chromatography
   ANTI-CANCER DRUGS
   
   W.J. Loos et al., "Determination of camptothecin analogs in biological matrices by high-performance liquid chromatography", ANTI-CANC D, 11(5), 2000, pp. 315-324
9. Takimoto, CH; Morrison, G; Harold, N; Quinn, M; Monahan, BP; Band, RA; Cottrell, J; Guemei, A; Llorens, V; Hehman, H; Ismail, AS; Flemming, D; Gosky, DM; Hirota, H; Berger, SJ; Berger, NA; Chen, AP; Shapiro, JD; Arbuck, SG; Wright, J; Hamilton, JM; Allegra, CJ; Grem, JL
   Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients
   JOURNAL OF CLINICAL ONCOLOGY
   
   C.H. Takimoto et al., "Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients", J CL ONCOL, 18(3), 2000, pp. 659-667
10. Couteau, C; Risse, ML; Ducreux, M; Lefresne-Soulas, F; Riva, A; Lebecq, A; Ruffie, P; Rougier, P; Lokiec, F; Bruno, R; Armand, JP
    Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors
    JOURNAL OF CLINICAL ONCOLOGY
    
    C. Couteau et al., "Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors", J CL ONCOL, 18(20), 2000, pp. 3545-3552
11. Vanhoefer, U; Achterrath, W; Wilke, H; Seeber, S
    Preclinical evaluation of irinotecan
    ONKOLOGIE
    
    U. Vanhoefer et al., "Preclinical evaluation of irinotecan", ONKOLOGIE, 23, 2000, pp. S2-S7
12. Jansman, FGA; Sleijfer, DT; Coenen, JLLM; De Graaf, JC; Brouwers, JRBJ
    Risk factors determining chemotherapeutic toxicity in patients with advanced colorectal cancer
    DRUG SAFETY
    
    F.G.A. Jansman et al., "Risk factors determining chemotherapeutic toxicity in patients with advanced colorectal cancer", DRUG SAFETY, 23(4), 2000, pp. 255-278
13. Boisdron-Celle, M; Boulanger, N; Gamelin, E
    Pharmacokinetic monitoring
    BULLETIN DU CANCER
    
    M. Boisdron-Celle et al., "Pharmacokinetic monitoring", B CANCER, 87(1), 2000, pp. 86-92
14. Pommier, Y; Pourquier, P; Urasaki, Y; Wu, JX; Laco, GS
    Topoisomerase I inhibitors: selectivity and cellular resistance
    DRUG RESISTANCE UPDATES
    
    Y. Pommier et al., "Topoisomerase I inhibitors: selectivity and cellular resistance", DRUG RESIST, 2(5), 1999, pp. 307-318
15. Mathijssen, RHJ; van Alphen, RJ; de Jonge, MJA; Verweij, J; de Bruijn, P; Loos, WJ; Nooter, K; Vernillet, L; Stoter, G; Sparreboom, A
    Sparse-data set analysis for irinotecan and SN-38 pharmacokinetics in cancer patients co-treated with cisplatin
    ANTI-CANCER DRUGS
    
    R.H.J. Mathijssen et al., "Sparse-data set analysis for irinotecan and SN-38 pharmacokinetics in cancer patients co-treated with cisplatin", ANTI-CANC D, 10(1), 1999, pp. 9-16
16. Ducreux, M; Ychou, M; Seitz, JF; Bonnay, M; Bexon, A; Armand, JP; Mahjoubi, M; Mery-Mignard, D; Rougier, P
    Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): A clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer
    JOURNAL OF CLINICAL ONCOLOGY
    
    M. Ducreux et al., "Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): A clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer", J CL ONCOL, 17(9), 1999, pp. 2901-2908
17. Wasserman, E; Cuvier, C; Lokiec, F; Goldwasser, F; Kalla, S; Mery-Mignard, D; Ouldkaci, M; Besmaine, A; Dupont-Andre, G; Mahjoubi, M; Marty, M; Misset, JL; Cvitkovic, E
    Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: Results of two independent phase I studies with pharmacokinetics
    JOURNAL OF CLINICAL ONCOLOGY
    
    E. Wasserman et al., "Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: Results of two independent phase I studies with pharmacokinetics", J CL ONCOL, 17(6), 1999, pp. 1751-1759
18. de Bruijn, P; de Jonge, MJA; Verweij, J; Loos, WJ; Nooter, K; Stoter, G; Sparreboom, A
    Femtomole quantitation of 7-ethyl-10-hydroxycamptothecine (SN-38) in plasma samples by reversed-phase high-performance liquid chromatography
    ANALYTICAL BIOCHEMISTRY
    
    P. de Bruijn et al., "Femtomole quantitation of 7-ethyl-10-hydroxycamptothecine (SN-38) in plasma samples by reversed-phase high-performance liquid chromatography", ANALYT BIOC, 269(1), 1999, pp. 174-178
19. RIVORY LP; FINDLAY M; CLARKE S; BISHOP J
    TRACE ANALYSIS OF SN-38 IN HUMAN PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY
    Journal of chromatography B. Biomedical sciences and applications
    
    L.P. Rivory et al., "TRACE ANALYSIS OF SN-38 IN HUMAN PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY", Journal of chromatography B. Biomedical sciences and applications, 714(2), 1998, pp. 355-359
20. HERBEN VMM; HUININK WWT; SCHELLENS JHM; BEIJNEN JH
    CLINICAL PHARMACOKINETICS OF CAMPTOTHECIN TOPOISOMERASE-I INHIBITORS
    Pharmacy world & science
    
    V.M.M. Herben et al., "CLINICAL PHARMACOKINETICS OF CAMPTOTHECIN TOPOISOMERASE-I INHIBITORS", Pharmacy world & science, 20(4), 1998, pp. 161-172
21. HECHT JR
    GASTROINTESTINAL TOXICITY OF IRINOTECAN
    Oncology
    
    J.R. Hecht, "GASTROINTESTINAL TOXICITY OF IRINOTECAN", Oncology, 12(8), 1998, pp. 72-78
22. IYER L; RATAIN MJ
    CLINICAL-PHARMACOLOGY OF CAMPTOTHECINS
    Cancer chemotherapy and pharmacology
    
    L. Iyer e M.J. Ratain, "CLINICAL-PHARMACOLOGY OF CAMPTOTHECINS", Cancer chemotherapy and pharmacology, 42, 1998, pp. 31-43
23. INABA M; OHNISHI Y; ISHII H; TANIOKA Y; YOSHIDA Y; SUDOH K; HAKUSUI H; MIZUNO N; ITO K; SUGIYAMA Y
    PHARMACOKINETICS OF CPT-11 IN RHESUS-MONKEYS
    Cancer chemotherapy and pharmacology
    
    M. Inaba et al., "PHARMACOKINETICS OF CPT-11 IN RHESUS-MONKEYS", Cancer chemotherapy and pharmacology, 41(2), 1998, pp. 103-108
24. TAKIMOTO CH; WRIGHT J; ARBUCK SG
    CLINICAL-APPLICATIONS OF THE CAMPTOTHECINS
    Biochimica et biophysica acta, N. Gene structure and expression
    
    C.H. Takimoto et al., "CLINICAL-APPLICATIONS OF THE CAMPTOTHECINS", Biochimica et biophysica acta, N. Gene structure and expression, 1400(1-3), 1998, pp. 107-119
25. SIU LL; ROWINSKY EK
    A RISK-BENEFIT ASSESSMENT OF IRINOTECAN IN SOLID TUMORS
    Drug safety
    
    L.L. Siu e E.K. Rowinsky, "A RISK-BENEFIT ASSESSMENT OF IRINOTECAN IN SOLID TUMORS", Drug safety, 18(6), 1998, pp. 395-417
26. ARBUCK SG; TAKIMOTO CH
    AN OVERVIEW OF TOPOISOMERASE-I - TARGETING AGENTS
    Seminars in hematology
    
    S.G. Arbuck e C.H. Takimoto, "AN OVERVIEW OF TOPOISOMERASE-I - TARGETING AGENTS", Seminars in hematology, 35(3), 1998, pp. 3-12
27. ROBERT J; RIVORY L
    PHARMACOLOGY OF IRINOTECAN
    Medicamentos de actualidad
    
    J. Robert e L. Rivory, "PHARMACOLOGY OF IRINOTECAN", Medicamentos de actualidad, 34(9), 1998, pp. 777-803
28. Chabot, GG; Robert, J; Lokiec, F; Canal, P
    Irinotecan pharmacokinetics
    BULLETIN DU CANCER
    
    G.G. Chabot et al., "Irinotecan pharmacokinetics", B CANCER, 1998, pp. 11-20
29. YAMAMOTO N; TAMURA T; NISHIWAKI Y; KURITA Y; KAWAKAMI Y; ABE S; NAKABAYASHI T; SUZUKI S; MATSUDA T; HAYASHI I; TAKAHASHI T; SAIJO N
    LIMITED SAMPLING MODEL FOR THE AREA UNDER THE CONCENTRATION VERSUS TIME CURVE OF IRINOTECAN AND ITS APPLICATION TO A MULTICENTRIC PHASE-II TRIAL
    Clinical cancer research
    
    N. Yamamoto et al., "LIMITED SAMPLING MODEL FOR THE AREA UNDER THE CONCENTRATION VERSUS TIME CURVE OF IRINOTECAN AND ITS APPLICATION TO A MULTICENTRIC PHASE-II TRIAL", Clinical cancer research, 3(7), 1997, pp. 1087-1092
30. GUPTA E; MICK R; RAMIREZ J; WANG XL; LESTINGI TM; VOKES EE; RATAIN MJ
    PHARMACOKINETIC AND PHARMACODYNAMIC EVALUATION OF THE TOPOISOMERASE INHIBITOR IRINOTECAN IN CANCER-PATIENTS
    Journal of clinical oncology
    
    E. Gupta et al., "PHARMACOKINETIC AND PHARMACODYNAMIC EVALUATION OF THE TOPOISOMERASE INHIBITOR IRINOTECAN IN CANCER-PATIENTS", Journal of clinical oncology, 15(4), 1997, pp. 1502-1510
31. CHABOT GG
    CLINICAL PHARMACOKINETICS OF IRINOTECAN
    Clinical pharmacokinetics
    
    G.G. Chabot, "CLINICAL PHARMACOKINETICS OF IRINOTECAN", Clinical pharmacokinetics, 33(4), 1997, pp. 245-259
32. OREILLY S; ROWINSKY EK
    THE CLINICAL STATUS OF IRINOTECAN (CPT-11), A NOVEL WATER-SOLUBLE CAMPTOTHECIN ANALOG - 1996
    Critical reviews in oncology/hematology
    
    S. Oreilly e E.K. Rowinsky, "THE CLINICAL STATUS OF IRINOTECAN (CPT-11), A NOVEL WATER-SOLUBLE CAMPTOTHECIN ANALOG - 1996", Critical reviews in oncology/hematology, 24(1), 1996, pp. 47-70
33. CANAL P; GAY C; DEZEUZE A; DOUILLARD JY; BUGAT R; BRUNET R; ADENIS A; HERAIT P; LOKIEC F; MATHIEUBOUE A
    PHARMACOKINETICS AND PHARMACODYNAMICS OF IRINOTECAN DURING A PHASE-IICLINICAL-TRIAL IN COLORECTAL-CANCER
    Journal of clinical oncology
    
    P. Canal et al., "PHARMACOKINETICS AND PHARMACODYNAMICS OF IRINOTECAN DURING A PHASE-IICLINICAL-TRIAL IN COLORECTAL-CANCER", Journal of clinical oncology, 14(10), 1996, pp. 2688-2695